Trial Outcomes & Findings for Effects of Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With Lateral Epicondylitis (NCT NCT04829734)
NCT ID: NCT04829734
Last Updated: 2025-08-29
Results Overview
Degree of pain rating will be measured by 0-100 horizontal Visual Analog Pain Scale, with with 0 being 'no pain' and 100 'the worst possible pain'
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
50 participants
Primary outcome timeframe
3 weeks (end of treatment)
Results posted on
2025-08-29
Participant Flow
Participant milestones
| Measure |
Active PBMT-sMF
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Overall Study
STARTED
|
25
|
25
|
|
Overall Study
COMPLETED
|
25
|
25
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effects of Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With Lateral Epicondylitis
Baseline characteristics by cohort
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
Total
n=50 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
34.64 years
STANDARD_DEVIATION 7.82 • n=5 Participants
|
35.12 years
STANDARD_DEVIATION 9.77 • n=7 Participants
|
34.88 years
STANDARD_DEVIATION 9.74 • n=5 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
10 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
23 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Hispanic/Latino
|
10 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
African American
|
4 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Region of Enrollment
Brazil
|
25 participants
n=5 Participants
|
25 participants
n=7 Participants
|
50 participants
n=5 Participants
|
|
Degree of pain rating (VAS)
|
79.36 units on a scale
STANDARD_DEVIATION 10.19 • n=5 Participants
|
75.60 units on a scale
STANDARD_DEVIATION 9.64 • n=7 Participants
|
77.48 units on a scale
STANDARD_DEVIATION 10.00 • n=5 Participants
|
|
Forearm Pain and Disability
|
58.26 units on a scale
STANDARD_DEVIATION 9.45 • n=5 Participants
|
59.28 units on a scale
STANDARD_DEVIATION 8.48 • n=7 Participants
|
58.77 units on a scale
STANDARD_DEVIATION 8.90 • n=5 Participants
|
|
Grip Strength
Affected/Treated Limb
|
23.13 kgf
STANDARD_DEVIATION 8.16 • n=5 Participants
|
24.24 kgf
STANDARD_DEVIATION 12.04 • n=7 Participants
|
23.69 kgf
STANDARD_DEVIATION 10.19 • n=5 Participants
|
|
Grip Strength
Unaffected/ Untreated Limb
|
24.71 kgf
STANDARD_DEVIATION 7.77 • n=5 Participants
|
27.55 kgf
STANDARD_DEVIATION 12.46 • n=7 Participants
|
26.13 kgf
STANDARD_DEVIATION 10.38 • n=5 Participants
|
|
TNF-α (Tumor Necrosis Factor-alpha) Levels
|
35.75 pg/ml
STANDARD_DEVIATION 4.99 • n=5 Participants
|
36.66 pg/ml
STANDARD_DEVIATION 6.96 • n=7 Participants
|
36.20 pg/ml
STANDARD_DEVIATION 6.01 • n=5 Participants
|
PRIMARY outcome
Timeframe: 3 weeks (end of treatment)Degree of pain rating will be measured by 0-100 horizontal Visual Analog Pain Scale, with with 0 being 'no pain' and 100 'the worst possible pain'
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Degree of Pain Rating (VAS)
|
36.92 units on a scale
Standard Deviation 22.64
|
51.40 units on a scale
Standard Deviation 19.84
|
SECONDARY outcome
Timeframe: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.Were measured using the Patient-Rated Tennis Elbow Evaluation (PRTEE), a 15-item questionnaire comprising five items related to pain and ten items related to function. Each item is rated on an 11-point scale ranging from 0 to 10, where 0 indicates no pain or difficulty and 10 indicates the worst imaginable pain or complete inability to perform the activity. The pain subscale score is obtained by summing the five pain items, yielding a maximum score of 50. The function subscale is calculated by summing the ten function items and dividing the total by 2, also resulting in a maximum score of 50. The total PRTEE score is the sum of the pain and function subscale scores, ranging from 0 (no pain or disability) to 100 (maximum pain and disability), with higher scores indicating greater impairment.
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Forearm Pain and Disability
Total scores - 3 weeks (end of treatment)
|
39.44 units on a scale
Standard Deviation 7.53
|
40.88 units on a scale
Standard Deviation 8.61
|
|
Forearm Pain and Disability
Total scores - 4 weeks after the conclusion of the treatment
|
29.60 units on a scale
Standard Deviation 10.67
|
33.34 units on a scale
Standard Deviation 9.68
|
|
Forearm Pain and Disability
Function scores - 3 weeks (end of treatment)
|
14.28 units on a scale
Standard Deviation 5.22
|
15.49 units on a scale
Standard Deviation 8.61
|
|
Forearm Pain and Disability
Function scores - 4 weeks after the conclusion of the treatment
|
10.72 units on a scale
Standard Deviation 7.09
|
11.14 units on a scale
Standard Deviation 6.36
|
SECONDARY outcome
Timeframe: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.The grip strength will be measured using a digital grip dynamometer type Jamar® Plus Digital Hand Dynamometer.
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Grip Strength
3 weeks (end of treatment) - Affected/Treated Limb
|
25.07 kgf
Standard Deviation 8.83
|
26.37 kgf
Standard Deviation 12.70
|
|
Grip Strength
4 weeks after the conclusion of the treatment - Affected/Treated Limb
|
25.97 kgf
Standard Deviation 7.53
|
27.72 kgf
Standard Deviation 12.60
|
|
Grip Strength
3 weeks (end of treatment) - Unaffected/Untreated Limb
|
25.45 kgf
Standard Deviation 9.28
|
26.67 kgf
Standard Deviation 12.57
|
|
Grip Strength
4 weeks after the conclusion of the treatment - Unaffected/Untreated Limb
|
26.07 kgf
Standard Deviation 8.72
|
28.39 kgf
Standard Deviation 11.23
|
SECONDARY outcome
Timeframe: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.The TNF-α levels will be measured by blood samples through the enzyme-linked immunosorbent assay (ELISA).
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
TNF-α (Tumor Necrosis Factor-alpha) Levels
3 weeks (end of treatment)
|
25.77 pg/ml
Standard Deviation 4.90
|
33.14 pg/ml
Standard Deviation 4.71
|
|
TNF-α (Tumor Necrosis Factor-alpha) Levels
4 weeks after the conclusion of the treatment
|
26.45 pg/ml
Standard Deviation 5.69
|
32.00 pg/ml
Standard Deviation 6.11
|
SECONDARY outcome
Timeframe: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.Subject satisfaction will be measured by 1-item Likert Scale. The scale uses the following responses: 5 = Very Satisfied; 4 = Somewhat Satisfied; 3 = Neither Satisfied nor Dissatisfied; 2 = Not Very Satisfied; 1 = Not at All Satisfied. Highest scores indicates better satisfaction.
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Subject Satisfaction With Overall Outcome Rating
3 weeks (end of treatment) · Very satisfied
|
18 Participants
|
16 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
3 weeks (end of treatment) · Somewhat Satisfied
|
6 Participants
|
6 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
3 weeks (end of treatment) · Neither
|
1 Participants
|
1 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
3 weeks (end of treatment) · Not Very Satisfied
|
0 Participants
|
2 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
3 weeks (end of treatment) · Not at All Satisfied
|
0 Participants
|
0 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
4 weeks after the conclusion of the treatment · Very satisfied
|
21 Participants
|
18 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
4 weeks after the conclusion of the treatment · Somewhat Satisfied
|
3 Participants
|
3 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
4 weeks after the conclusion of the treatment · Neither
|
1 Participants
|
3 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
4 weeks after the conclusion of the treatment · Not Very Satisfied
|
0 Participants
|
1 Participants
|
|
Subject Satisfaction With Overall Outcome Rating
4 weeks after the conclusion of the treatment · Not at All Satisfied
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.Adverse events will be measured by report.
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Presence of Adverse Events
Tingling sensation
|
0 participants
|
1 participants
|
|
Presence of Adverse Events
Biting sensation
|
1 participants
|
0 participants
|
|
Presence of Adverse Events
Heating of skin sensation
|
1 participants
|
0 participants
|
|
Presence of Adverse Events
Pain and discomfort
|
0 participants
|
2 participants
|
SECONDARY outcome
Timeframe: 4 weeks after the conclusion of the treatment.Degree of pain rating will be measured by 0-100 horizontal Visual Analog Pain Scale, with with 0 being 'no pain' and 100 'the worst possible pain'
Outcome measures
| Measure |
Active PBMT-sMF
n=25 Participants
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 Participants
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Degree of Pain Rating (VAS)
|
20.28 units on a scale
Standard Deviation 21.24
|
37.40 units on a scale
Standard Deviation 24.08
|
Adverse Events
Active PBMT-sMF
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Placebo PBMT-sMF
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Active PBMT-sMF
n=25 participants at risk
Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Active PBMT-sMF: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
|
Placebo PBMT-sMF
n=25 participants at risk
Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
Placebo PBMT-sMF: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
|
|---|---|---|
|
Skin and subcutaneous tissue disorders
Biting sensation
|
4.0%
1/25 • Number of events 1 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
0.00%
0/25 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
|
Skin and subcutaneous tissue disorders
Heating
|
4.0%
1/25 • Number of events 6 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
0.00%
0/25 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
|
Musculoskeletal and connective tissue disorders
Pain
|
0.00%
0/25 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
8.0%
2/25 • Number of events 3 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
|
Skin and subcutaneous tissue disorders
Tingling sensation
|
0.00%
0/25 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
4.0%
1/25 • Number of events 1 • 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment.
|
Additional Information
Douglas Johnson, ATC, EES, CLS - Chief Science Officer, Clinical and Scientific Affairs
Multi Radiance Medical
Phone: 440-542-0761
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place